Comparative Pharmacology
Head-to-head clinical analysis: AREDIA versus BONSITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AREDIA versus BONSITY.
AREDIA vs BONSITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
Selective estrogen receptor modulator (SERM); binds to estrogen receptors, exerting agonistic effects on bone and lipid metabolism and antagonistic effects on breast and uterine tissue.
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
10 mg orally once daily, taken with or without food.
None Documented
None Documented
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Terminal elimination half-life is approximately 24-30 hours; this supports once-daily dosing. Half-life may be prolonged in renal impairment.
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination comprises 20-25% as metabolites and unchanged drug.
Category C
Category C
Bisphosphonate
Bisphosphonate